This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Barclays analyst Adrienne Yih downgraded the rating for Foot Locker, Inc. FL from Overweight to Equal-Weight and raised the price target from $14 to $24. Foot Locker shares closed at $23.90 on Thursday. See how other analysts view this stock.
UBS analyst David Dai downgraded Iovance Biotherapeutics, Inc. IOVA from Buy to Neutral and lowered the price target from $17 to $2. Iovance Biotherapeutics shares closed at $1.76 on Thursday. See how other analysts view this stock.
Baird analyst Joel Beatty downgraded Neurogene Inc. NGNE from Outperform to Neutral and slashed the price target from $38 to $24. Neurogene shares closed at $19.37 on Thursday. See how other analysts view this stock.

Considering buying FL stock? Here’s what analysts think:

Pre-IPO Offer: Get A Piece Of A Nearly $5T Global Opportunity By Joining BOXABL As An Early Shareholder At Just $0.80/Share

Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.